277 related articles for article (PubMed ID: 32026157)
21. Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.
Ornstein MC; Wood L; Elson P; Allman K; Beach J; Martin A; Gilligan T; Garcia JA; Rini BI
Clin Genitourin Cancer; 2017 Apr; 15(2):e275-e280. PubMed ID: 27625016
[TBL] [Abstract][Full Text] [Related]
22. Renal cell carcinoma: applicability of the apparent coefficient of the diffusion-weighted estimated by MRI for improving their differential diagnosis, histologic subtyping, and differentiation grade.
Mytsyk Y; Dutka I; Borys Y; Komnatska I; Shatynska-Mytsyk I; Farooqi AA; Gazdikova K; Caprnda M; Rodrigo L; Kruzliak P
Int Urol Nephrol; 2017 Feb; 49(2):215-224. PubMed ID: 27853915
[TBL] [Abstract][Full Text] [Related]
23. Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI.
Mytsyk Y; Dutka I; Yuriy B; Maksymovych I; Caprnda M; Gazdikova K; Rodrigo L; Kruzliak P; Illjuk P; Farooqi AA
Int Urol Nephrol; 2018 Feb; 50(2):197-204. PubMed ID: 29230706
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
Matrana MR; Duran C; Shetty A; Xiao L; Atkinson BJ; Corn P; Pagliaro LC; Millikan RE; Charnsangave C; Jonasch E; Tannir NM
Eur J Cancer; 2013 Oct; 49(15):3169-75. PubMed ID: 23810246
[TBL] [Abstract][Full Text] [Related]
25. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
[TBL] [Abstract][Full Text] [Related]
26. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Grassi P; Verzoni E; Ratta R; Porcu L; Prisciandaro M; Mennitto A; Calareso G; de Braud F; Procopio G
Drugs R D; 2017 Sep; 17(3):461-467. PubMed ID: 28801802
[TBL] [Abstract][Full Text] [Related]
27. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
[TBL] [Abstract][Full Text] [Related]
28. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
Wagstaff J; Jones R; Hawkins R; Porfiri E; Pickering L; Bahl A; Brown J; Buchan S
Ann Oncol; 2016 Jan; 27(1):159-65. PubMed ID: 26489444
[TBL] [Abstract][Full Text] [Related]
29. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
30. Diffusion-weighted magnetic resonance imaging for early response assessment of chemoradiotherapy in patients with nasopharyngeal carcinoma.
Chen Y; Liu X; Zheng D; Xu L; Hong L; Xu Y; Pan J
Magn Reson Imaging; 2014 Jul; 32(6):630-7. PubMed ID: 24703576
[TBL] [Abstract][Full Text] [Related]
31. Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.
Queiroz Muniz D; Ratto B; Yang H; Zhao J; Jenkins M; Signorovitch J; Dezzani L; Salman P; Lema Medina M; Lopera D; Lerzo G; Del Castillo C; Chacon M; Martin A; Campos-Gomez S
Adv Ther; 2019 Dec; 36(12):3446-3457. PubMed ID: 31630333
[TBL] [Abstract][Full Text] [Related]
32.
Mittlmeier LM; Unterrainer M; Rodler S; Todica A; Albert NL; Burgard C; Cyran CC; Kunz WG; Ricke J; Bartenstein P; Stief CG; Ilhan H; Staehler M
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2031-2037. PubMed ID: 33369689
[TBL] [Abstract][Full Text] [Related]
33. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
34. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
35. The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy.
Wang L; Liu L; Han C; Liu S; Tian H; Li Z; Ren X; Shi G; Wang Q; Wang G
Radiother Oncol; 2016 Nov; 121(2):246-251. PubMed ID: 27838148
[TBL] [Abstract][Full Text] [Related]
36. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.
Nathan PD; Vinayan A; Stott D; Juttla J; Goh V
Cancer Biol Ther; 2010 Jan; 9(1):15-9. PubMed ID: 20009542
[TBL] [Abstract][Full Text] [Related]
37. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Ishihara H; Yagisawa T; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
Int J Clin Oncol; 2017 Feb; 22(1):126-135. PubMed ID: 27549785
[TBL] [Abstract][Full Text] [Related]
38. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.
Masini C; Vitale MG; Maruzzo M; Procopio G; de Giorgi U; Buti S; Rossetti S; Iacovelli R; Atzori F; Cosmai L; Vignani F; Prati G; Scagliarini S; Guida A; Berselli A; Pinto C
Clin Genitourin Cancer; 2019 Feb; 17(1):e150-e155. PubMed ID: 30396828
[TBL] [Abstract][Full Text] [Related]
40. Differentiating papillary type I RCC from clear cell RCC and oncocytoma: application of whole-lesion volumetric ADC measurement.
Paschall AK; Mirmomen SM; Symons R; Pourmorteza A; Gautam R; Sahai A; Dwyer AJ; Merino MJ; Metwalli AR; Linehan WM; Malayeri AA
Abdom Radiol (NY); 2018 Sep; 43(9):2424-2430. PubMed ID: 29520425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]